RainDance Technologies, which sells systems that perform non-invasive genetic analysis, filed on Friday with the SEC to raise up to $60 million in an initial public offering.
Genetic testing companies have been active in the IPO market this year. Invitae (NVTA) has gained 19% after it priced above the range in February. Autogenomics (AGMX) and AltheaDx (IDGX) planned to go public in February but postponed their deals. HTG Molecular (HTGM) recently updated its financials and could launch an IPO soon.
RainDance lists Agilent Technologies (NYSE: A), Illumina (NASDAQ: ILMN) and Qiagen (NASDAQ: QGEN) among its competitors.
The Billerica, MA-based company, which was founded in 2004 and booked $31 million in sales for the 12 months ended December 31, 2014, plans to list on the NASDAQ under the symbol RAIN. It initially filed confidentially on May 12, 2014. BofA Merrill Lynch, Cowen & Company and Evercore Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
